Market News AIOpen the app

ALMS stock news · Alumis Inc.

Stories about Alumis Inc. (ALMS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ALMS

Follow Alumis Inc. (ALMS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALMS
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:19 PM ET · Market

    Alumis Inc. shared its Q3 2026 results and plans to submit a new drug application for envudeucitinib.

    Neutral

    Alumis reported psoriasis gains and an FDA filing still on track for the fourth quarter of 2026. Its lupus study missed its main goals overall, leaving mixed results.

  2. Sep 1, 2026, 11:11 AM ET · Trial

    Alumis stock declines on Tuesday following unmet goals in Phase 2b LUMUS trial.

    Bad for ALMS

    Alumis Inc. stock is trading lower after the company announced that its Phase 2b LUMUS trial for envudeucitinib did not meet its primary or secondary endpoints, leading to a significant drop in share price.